Previous 10 | Next 10 |
2024-03-08 15:30:02 ET H.C. Wainwright analyst issues BUY recommendation for EYPT on March 8, 2024 03:00PM ET. The previous analyst recommendation was Buy. EYPT was trading at $24.48 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
2024-03-07 12:29:03 ET EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2023 Earnings Conference Call March 07, 2024, 08:30 AM ET Company Participants George Elston - EVP and CFO Jay Duker - President and CEO Ramiro Ribeiro - Chief Medical Officer Conference Call P...
2024-03-07 07:04:05 ET More on EyePoint Pharmaceuticals EyePoint Is Betting The Bank On EYP-1901 EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time JP Morgan starts EyePoint at overweight, cites eye drug potential Seeking Alpha ...
– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieving all primary and secondary endpoints; initiation of the first Phase 3 clinical trial expected in 2H 2024 – – Dosed first patient in Phase 2 VERONA clin...
Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...
2024-03-06 10:28:05 ET More on EyePoint Pharmaceuticals EyePoint Is Betting The Bank On EYP-1901 EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time JP Morgan starts EyePoint at overweight, cites eye drug potential Seeking Alpha ...
– Company on-track to report topline data in 2Q 2024 for the Phase 2 PAVIA clinical trial of EYP-1901 in moderately severe-to-severe NPDR – – Initiation of first Phase 3 clinical trial (LUGANO) of EYP-1901 in wet AMD expected in 2H 2024 – WATERTOWN, M...
WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webca...
2024-02-21 08:36:08 ET Summary EyePoint's EYP-1901 shows promising results in a Phase 2 trial for multiple eye conditions, potentially becoming the standard of care. The company has a strong drug delivery platform with Durasert and has sold off its profitable YUTIQ business. E...
2024-02-20 13:50:53 ET Summary EyePoint Pharmaceuticals' EYP-1901 drug for wet AMD showed positive results in Phase 2 clinical trials, potentially offering a lower-cost and more effective treatment option. The company's proprietary Durasert E technology delivers drugs directly to ...
News, Short Squeeze, Breakout and More Instantly...
EyePoint Pharmaceuticals Inc. Company Name:
EYPT Stock Symbol:
NASDAQ Market:
EyePoint Pharmaceuticals Inc. Website:
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical tria...
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R...